PRME
Prime Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.70
−0.27%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.1M | 4.6M | 3.0M | — | — |
| Cost of Revenue | 45.8M | 7.3M | — | — | — |
| Gross Profit | (41.8M) | (2.7M) | 3.0M | — | — |
| Operating Expenses | |||||
| R&D Expense | 146.2M | 160.6M | 155.3M | 147.9M | 86.7M |
| SG&A Expense | 54.4M | 52.3M | 50.2M | 43.4M | 29.8M |
| General & Admin Expense | 54.4M | 52.3M | 50.2M | 43.4M | 29.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (45.8M) | (7.3M) | — | 13.5M | — |
| Total Operating Expenses | 154.7M | 205.7M | 205.4M | 204.8M | 116.5M |
| Cost and Expenses | 200.6M | 213.0M | 205.4M | 204.8M | 116.5M |
| Operating Income (EBIT) | (196.5M) | (208.3M) | (202.5M) | (204.8M) | (116.5M) |
| Non-Operating | |||||
| Interest Income | 4.5M | 4.1M | 3.5M | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 4.5M | 4.1M | 3.5M | — | — |
| Other Non-Op Income/Expense | 8.6M | 7.2M | 6.6M | 6.4M | (6.2M) |
| Non-Operating Income (excl Interest) | (8.6M) | (7.2M) | (6.6M) | (13.5M) | 6.2M |
| EBT (Pre-Tax Income) | (187.9M) | (201.1M) | (195.9M) | (198.4M) | (122.8M) |
| Income Tax Expense | — | — | — | (279.0K) | (948.0K) |
| Bottom Line | |||||
| Net Income | (187.9M) | (201.1M) | (195.9M) | (198.1M) | (121.8M) |
| Earnings from Cont. Ops | (187.9M) | (201.1M) | (195.9M) | (198.1M) | (121.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (187.9M) | (201.1M) | (195.9M) | (198.1M) | (142.0M) |
| Per Share | |||||
| Basic EPS | ($1.10) | ($1.35) | ($1.65) | ($2.18) | ($1.46) |
| Diluted EPS | ($1.10) | ($1.35) | ($1.65) | ($2.18) | ($1.46) |
| Revenue Per Share | $0.02 | $0.03 | $0.03 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 177.2M | 148.8M | 118.6M | 91.0M | 97.2M |
| Diluted Shares Outstanding | 177.2M | 148.8M | 118.6M | 91.0M | 97.2M |
| Profitability Metrics | |||||
| EBITDA | (180.5M) | (195.8M) | (189.8M) | (186.6M) | (120.5M) |
| D&A | 7.4M | 5.4M | 6.1M | 4.7M | 2.2M |
| EBIT | (187.9M) | (201.1M) | (195.9M) | (191.3M) | (122.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026